STSA 64th Annual Meeting Program Changes

Unless otherwise noted in this addendum or verbally by speakers, participants have no relevant financial or regulatory relationships to disclose. Participants listed with a D next to their name have indicated that they do have a financial and/or regulatory disclosure and that disclosure is listed immediately below their name.

----------------------------------------------------------------------------------------------------------------------------------

PRESENTER CHANGES

ETHICS DEBATE (Thursday | Nov. 9 | 7:20 am – 7:35 am)
Battling the Chimera: How Much Disclosure of Rare Risks Is Necessary?
Con: D*Joseph Zwischenberger, University of Kentucky, Lexington, KY

BASIC SCIENCE FORUM (Thursday | Nov. 9 | 7:24 am – 7:32 am)
4B. Correlating Oxygen Delivery on Cardiopulmonary Bypass With the Neurological Injury Biomarker UCH-L1: Charles Fraser, Johns Hopkins School of Medicine, Baltimore, MD

FIRST SCIENTIFIC SESSION (Thursday | Nov. 9 | 9:30 am – 9:45 am)

FOURTH SCIENTIFIC SESSION A: Adult Cardiac Breakout (Friday | Nov. 10 | 7:00 am – 7:15 am)
23. Repair of Thoracic and Thoracoabdominal Mycotic Aneurysms and Infected Aortic Grafts Using Cryopreserved Allograft: David Blitzer, Indiana University Health, Indianapolis, IN

FOURTH SCIENTIFIC SESSION A: Adult Cardiac Breakout (Friday | Nov. 10 | 7:30 am – 7:45 am)
25V. Leaflet Reconstructive Techniques for Aortic Valve Repair: D*J. Scott Rankin, West Virginia University, Morgantown, WV

FOURTH SCIENTIFIC SESSION A: Congenital Breakout (Friday | Nov. 10 | 8:15 am – 8:30 am)
40. Less is More in Post Pediatric Heart Transplant Care: Samantha Wagner, University of Iowa Children’s Hospital

----------------------------------------------------------------------------------------------------------------------------------

DISCUSSANT CHANGES

FIRST SCIENTIFIC SESSION (Thursday | Nov. 9 | 9:00 am – 9:15 am)
5. Safety of Next Day Discharge Following Lobectomy: Have We Broken The Speed Limit? Discussant: *Reza Mehran, University of Texas, MD Anderson Cancer Center, Houston, TX

SECOND SCIENTIFIC SESSION (Thursday | Nov. 9 | 2:30 pm – 2:45 pm)
13. Federal Litigation of Cardiac Surgery: Neurologic Injury Predicts Plaintiff Success: *Richard Lee, St. Louis University, St. Louis, MO

THIRD SCIENTIFIC SESSION (Thursday | Nov. 9 | 5:00 pm – 5:15 pm)
21. Use of a Bare Metal Stent in Addition to a Covered Endograft for Management of Complicated Acute Type B Aortic Dissection Offers Positive Remodeling for the Thoracoabdominal Aorta Discussant: D*Bradley Leshnower, Emory University, Atlanta, GA

FOURTH SCIENTIFIC SESSION A: Adult Cardiac Breakout (Friday | Nov. 10 | 7:15 am – 7:30 am)
24. Outcomes of Planned 2-Stage Hybrid Aortic Repair With Dacron Replaced Proximal Landing Zone Discussant: D*Scott LeMaire, Baylor College of Medicine, Houston, TX

*STSA Member  D Relationship Disclosure
## ADDITIONAL EXHIBITORS

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth:</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Innovations</td>
<td>210</td>
<td>Hillsboro, OR 97124</td>
</tr>
<tr>
<td>Admedus</td>
<td>309</td>
<td>Minneapolis, MN 55437</td>
</tr>
<tr>
<td>Getinge</td>
<td>105</td>
<td>Wayne, NJ 07470</td>
</tr>
<tr>
<td>Johnson &amp; Johnson Medical Devices</td>
<td>211-213</td>
<td>New Brunswick, NJ 08933</td>
</tr>
<tr>
<td>MiMedx</td>
<td>310</td>
<td>Marietta, GA 30062</td>
</tr>
</tbody>
</table>

**Acute Innovations**


**Admedus**

ADMEDUS, is a global healthcare company, dedicated to bringing innovative medical technologies to market. CardioCel® and CardioCel Neo are cardiovascular biomaterial scaffolds, engineered with ADAPT® Technology, for simple and complex cardiac defects. ADAPT processed biomaterials offer unparalleled biocompatibility and calcium resistance. Admedus’ new shaped collagen product, CardioCel 3D, also made with ADAPT Technology, is intended to optimize great vessel reconstruction in neonates.

**Getinge**

Getinge is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We employ more than 15,500 people, and have operations in 41 countries.

**Johnson & Johnson Medical Devices**

Having made significant contributions to surgery for more than a century, the Johnson & Johnson Medical Devices Companies are in the business of reaching more patients and restoring more lives. The group represents the most comprehensive surgical technology and specialty solutions business in the world, offering an unparalleled breadth of products, services, programs and research and development capabilities directed at advancing patient care while delivering clinical and economic value to health care systems worldwide.

**MiMedx**

MiMedx® is the global premier processor, marketer, and distributor of human amniotic tissue. MiMedx® has distributed over 1,000,000 amniotic tissue grafts worldwide and achieved profound clinical outcomes in multiple therapeutic areas including ophthalmology, spine, chronic wounds, dental, orthopedic surgery, sports medicine, urology, colorectal, and most recently thoracic. With this groundbreaking human tissue offering that promotes bioactive healing, MiMedx® believes its unmatched knowledge and superior processing of amniotic tissue strategically positions the Company to become the leader in regenerative medicine.
64th Annual Meeting Scientific Paper Corrections

Corrected information listed in the table for abstract #27 is as follows. All other abstract information as published in the Program Book is accurate. Download the complete Program Book at www.stsa.org

27. Functional Outcomes of Non-aneurysmal Type I Bicuspid Aortic Valve Repair With Annular Stabilization: Subcommissural Annuloplasty Versus External Subannular Aortic Ring

Presenting Author: Prashanth Vallabhajosyula, University of Pennsylvania, Philadelphia, PA

(Table 1) has a correction referenced on page 113. The last row of the table is currently labeled Cusp billowing (mm). The correct parameter is Leaflet prolapse (mm). The numbers in the subsequent columns remain accurate.

Reference page 112 for additional abstract information.

DISCLOSURE UPDATES

THIRD SCIENTIFIC SESSION (Thursday | Nov. 9 | 4:30 pm – 4:45 pm)

19. A Propensity Matched Analysis of Robotic, Minimally Invasive, and Conventional Mitral Valve Surgery

Discussant: Dr. Joseph Sabik, Consultant/Advisory Board: Medtronic, Cardiac Surgery Advisory Board; Other Research Support: Abbott, Surgical PI for EXCEL Trial

THIRD SCIENTIFIC SESSION (Thursday | Nov. 9 | 4:45 pm – 5:00 pm)

20. Patient Outcomes After Stent Failure for the Treatment of Acute Esophageal Perforation

Regulatory Disclosure: This presentation describes the off-label use of an esophageal stent for the treatment of an acute esophageal perforation.

FOURTH SCIENTIFIC SESSION C: Adult Cardiac Breakout (Friday | Nov. 10 | 11:00 am – 11:15 am)

51V. Hybrid Surgical Mitral Valve Replacement With a Transcatheter Valve in the Setting of Mitral Annular Calcification

Regulatory Disclosure: This presentation describes the off-label use of the Sapien 3 valve with a surgically added felt cuff in the mitral valve position. The valve was deployed during open surgery in the mitral valve position in the setting of mitral annular calcification.

MODERATOR CHANGES

HAROLD URSCHEL HISTORY LECTURESHIP (Friday | Nov. 10 | 2:30 pm – 3:00 pm)

67. Mark M. Ravitch: Southern Comfort and Curmudgeonry

*David R. Jones, Memorial Sloan-Kettering Cancer Center, New York, NY